myeloma Archives

CellCentric Secures £90M in Series C Funding to Propel Innovative Oral Treatment for Multiple Myeloma

Cambridge, England – CellCentric, a biotechnology firm focused on developing cancer therapies, has successfully secured £90 million in a Series C funding round aimed at advancing its innovative treatment for multiple myeloma, known as inobrodib. The funding round was co-led by RA Capital Management and newcomer Forbion, with additional investment from Avego Bioscience Capital and BrightEdge, the venture capital arm of the American Cancer Society. This latest infusion of capital will assist in propelling CellCentric’s …

Study Shows Increased Utilization of Hospice Facilities in End-of-Life Care for Multiple Myeloma Patients

Boston, Massachusetts – A recent study analyzed trends in place of death (POD) for multiple myeloma (MM) patients in the United States from 2003 to 2020. Multiple myeloma is a type of cancer that affects plasma cells and carries high morbidity and mortality rates. While modern treatments have improved care, a significant number of patients still succumb to the disease. The analysis, conducted using data from the Centers for Disease Control and Prevention, focused on …

FDA Panel Votes to Support CAR-T Therapies by Johnson & Johnson and Bristol Myers Squibb for Multiple Myeloma Treatment

Silver Spring, Maryland – An FDA advisory committee voted overwhelmingly in favor of recommending the approval of CAR-T therapies from Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee’s support for these therapies highlights a significant milestone in the ongoing discussions surrounding the use of CAR-T treatments in cancer care. During the committee meeting, concerns were raised about the higher rate of early deaths observed in …

New Concerns Arise Over Early Deaths in CAR-T Myeloma Trials with Carvykti and Abecma

Washington, D.C. – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T therapies used to treat multiple myeloma. Specifically, the FDA flagged the experimental treatments Carvykti from J&J and Legend, as well as Abecma from Bristol Myers Squibb. During the trials, patients receiving these CAR-T therapies experienced unexpected deaths, prompting the FDA to issue a warning. While CAR-T therapies have shown promising results in treating certain types …

Innovative Treatment for Multiple Myeloma Cancer Delivers 90% Effectiveness, Offering Hope for Patients

The city and state of New York has seen a groundbreaking development in the treatment of multiple myeloma, a type of blood cancer. Recent advances in treatment options have led to improved outcomes and increased survival rates for patients. These advances have transformed what was once considered a fatal diagnosis into a more manageable and treatable condition. One patient, Judith Harding, who was given a grim prognosis after her diagnosis in 2009, has now survived …

Voice actor of Max Payne passes away at the age of 65 after battling multiple myeloma

NEW YORK, NY – American actor James McCaffrey has passed away at the age of 65 after a long battle with multiple myeloma, a form of blood cancer, according to Variety. McCaffrey was best known for his role as the voice of Max Payne in the popular video game series, as well as his recent portrayal of Alex Casey in “Alan Wake 2.” He was first diagnosed with multiple myeloma, a rare and aggressive form …